Sugi Predict

Sugi Predict / Targets / PTPN4

PTPN4

Tyrosine-protein phosphatase non-receptor type 4 · P29074 · PTPN4 on Sugi Atlas →

175 patent compounds predicted against PTPN4, 120 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL6448091 SCHEMBL6448091 0.61 3/20
SCHEMBL29201710 SCHEMBL29201710 0.61 3/20
SCHEMBL97998 SCHEMBL97998 0.60 3/20
SCHEMBL14684688 SCHEMBL14684688 0.58 3/20
SCHEMBL14287841 SCHEMBL14287841 0.51 3/20
SCHEMBL12085755 SCHEMBL12085755 0.50 3/20
SCHEMBL19008528 SCHEMBL19008528 0.47 3/20
SCHEMBL806049 SCHEMBL806049 0.47 3/20
SCHEMBL17488976 SCHEMBL17488976 0.47 3/20
SCHEMBL17537488 SCHEMBL17537488 0.47 3/20
SCHEMBL6549541 SCHEMBL6549541 0.46 3/20
SCHEMBL28106722 SCHEMBL28106722 0.46 3/20
SCHEMBL18486476 SCHEMBL18486476 0.45 3/20
SCHEMBL10882955 SCHEMBL10882955 0.45 3/20
SCHEMBL18037951 SCHEMBL18037951 0.45 3/20
SCHEMBL6318721 SCHEMBL6318721 0.45 3/20
SCHEMBL5668125 SCHEMBL5668125 0.44 3/20
SCHEMBL21642988 SCHEMBL21642988 0.44 3/20
SCHEMBL28000594 SCHEMBL28000594 0.44 3/20
SCHEMBL28123560 SCHEMBL28123560 0.44 3/20

Clinical trials — most relevant to PTPN4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance PHASE4UNKNOWN
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia PHASE3RECRUITING
Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC PHASE2/PHASE3NOT_YET_RECRUITING
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) PHASE1/PHASE2WITHDRAWN
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation PHASE2UNKNOWN
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease PHASE2COMPLETED
An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer PHASE2RECRUITING
A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma PHASE2UNKNOWN
Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer PHASE2UNKNOWN
Study in Adult Ph-positive ALL PHASE2UNKNOWN
Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma PHASE2COMPLETED
Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma PHASE2ACTIVE_NOT_RECRUITING
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors PHASE1WITHDRAWN
A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors PHASE1RECRUITING
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers PHASE1COMPLETED
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency PHASE1RECRUITING
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease nanUNKNOWN
rT3 and Inflammation in Hashimoto's Thyroiditis nanCOMPLETED
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients. nanCOMPLETED
Immunophenotypic Evaluation of CD305 and CD85d in B-Cell Lymphoid Neoplasms nanNOT_YET_RECRUITING
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure nanUNKNOWN
Resistance to Immunotherapy in Gastric Cancer nanUNKNOWN
Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Single-nucleotide Polymorphism in Primary Immune Thrombocytopenic Purpura in Children nanNOT_YET_RECRUITING
Quantification of GADD34 Expression in RA nanCOMPLETED
Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognitive Impairment nanNOT_YET_RECRUITING
What is the Impact of TKI on Thyroid Function in CML Patients? nanNOT_YET_RECRUITING
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s) nanNOT_YET_RECRUITING
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a PTPN4 binder may also engage these)

ProteinNameSimilarity
Q9WU22 — 1.000 Q9WU22 →
Q6P0D7 — 0.981 Q6P0D7 →
MAP4K3 Mitogen-activated protein kinase kinase kinase kinase 3 0.979 landscape →
Q99JP0 — 0.979 Q99JP0 →
Q9R0C8 — 0.978 Q9R0C8 →
Q92796 — 0.977 Q92796 →
Q5U4T3 — 0.977 Q5U4T3 →
Q8BPM2 — 0.976 Q8BPM2 →
MAP4K5 Mitogen-activated protein kinase kinase kinase kinase 5 0.976 landscape →
Q07139 — 0.976 Q07139 →
B2RQE8 — 0.975 B2RQE8 →
A7MBL8 — 0.975 A7MBL8 →
Q07722 — 0.975 Q07722 →
A2ALK8 — 0.974 A2ALK8 →
B4F7E7 — 0.974 B4F7E7 →
Q9H8V3 — 0.974 Q9H8V3 →
Q5R8M5 — 0.973 Q5R8M5 →
Q62245 — 0.973 Q62245 →
B0KWC1 — 0.973 B0KWC1 →
Q0P4Q4 — 0.973 Q0P4Q4 →
PLCB1 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 0.972 landscape →
O08561 — 0.972 O08561 →
Q6NRZ4 — 0.972 Q6NRZ4 →
P28191 — 0.971 P28191 →
Q924I2 — 0.971 Q924I2 →
Q5M7Y0 — 0.971 Q5M7Y0 →
O02810 — 0.971 O02810 →
Q04982 — 0.971 Q04982 →
Q5PYH7 — 0.970 Q5PYH7 →
A8KBF6 — 0.970 A8KBF6 →